Kevzara: how international patients access US-sourced specialty supply

This page is informational, not medical advice. Always work with a licensed treating physician on prescribing decisions. Reserve Meds does not make insurance or pharmacy-assistance-program promises.

Quick orientation

Kevzara (sarilumab) is sponsored by Sanofi / Regeneron and received first US FDA approval in 2017. It is delivered as subcutaneous injection every 2 weeks. The US label covers adult patients with moderately-to-severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs; adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. Mechanistically, Sarilumab is a fully human monoclonal antibody that binds the interleukin-6 receptor (IL-6R).

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

US wholesale acquisition cost (WAC) is the published US specialty-distribution list price and is not the same as a single-payer negotiated price. US WAC for Kevzara commonly produces an annual drug-only cost around USD 40,000 to USD 45,000. Patient out-of-pocket via cross-border supply is the US WAC plus logistics, IOR / customs, translation, and a Reserve Meds concierge fee; it is not a route to local-formulary pricing.

Mechanism of action

Sarilumab is a fully human monoclonal antibody that binds the interleukin-6 receptor (IL-6R). Blocking IL-6 signaling reduces the systemic-inflammation drive central to rheumatoid arthritis pathology. The 2023 PMR expansion put a steroid-sparing IL-6R biologic in front of patients who would otherwise stay on long-term corticosteroids with cumulative toxicity.

Why Kevzara routes via cross-border NPP internationally

Sarilumab is registered widely but reimbursement remains uneven, and the polymyalgia rheumatica indication is newer than most regional formulary updates. Adult PMR patients trapped on long-term corticosteroids, and RA patients refractory to or intolerant of TNF-inhibitors, frequently route to Kevzara via named-patient import.

The patterns that produce cross-border demand for Kevzara are consistent across destination countries: meaningful registration lag relative to the US label, indication-specific dosing complexity that makes substitution clinically risky, payer denial patterns that exclude newer or expanded indications, and the global specialty distribution model in which the originator manufacturer routes specialty supply through a small number of authorized US wholesalers. Reserve Meds sits inside that authorized supply lane, not outside it.

How Reserve Meds coordinates supply

Every Kevzara case follows the same physician-led, document-first workflow:

1. The treating physician issues a prescription and clinical justification letter.
2. Reserve Meds clinical and regulatory review assesses indication fit and destination-country pathway eligibility.
3. Country-specific named-patient or personal-import documentation is prepared, translated where required, and submitted to the destination-country regulator under the local lawful import framework.
4. Supply is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability (a federal track-and-trace requirement) and unbroken chain of custody from US warehouse forward.
5. Cold-chain handling is validated where applicable; temperature is monitored end-to-end with audit logs.
6. Shipment is coordinated to the patient's treating physician or hospital pharmacy, not directly to consumers.

Reserve Meds does not handle controlled substances. We do not promise pharmacy assistance program enrollment, manufacturer copay support, or insurance reimbursement; those are different commercial frameworks aimed at US-domiciled patients.

Common cross-border destinations

Kevzara cross-border demand concentrates in markets where US specialty supply is the most reliable path to the labeled indication. We publish destination-country deep-dives where local matrix cells exist; the rest are coordinated case-by-case on the same physician-led workflow.

Across each of these destinations, three structural patterns repeat. First, the local regulator maintains a named-patient or personal-import framework precisely so clinicians can reach a labeled US therapy for individual patients whose case cannot wait for full local registration. Second, that framework is document-driven, which means the work of cross-border access is the work of preparing a defensible clinical and regulatory dossier rather than chasing inventory. Third, the destination-country specialist (the treating physician) signs the case in; Reserve Meds operates on top of that signature, not in place of it.

Real cost picture

Annual drug-only cost at US WAC commonly runs USD 40,000 to USD 45,000. Cold-chain logistics, IOR, customs, and translation costs apply. Reserve Meds quotes firm pricing post-document review.

A formal Reserve Meds quote breaks out: drug cost at US WAC; cold-chain 3PL handling where applicable; IOR, customs, and destination-country regulatory fees; certified translation of physician documentation; and a tiered Reserve Meds concierge fee layered on the drug cost rather than per-dose. The indicative range above is for orientation; a firm quote is issued after physician documentation is reviewed.

Reserve Meds does not charge intake deposits. Patients pay the firm-quoted amount in full only after accepting the quote, with a defined refund posture for procurement failure or gross negligence as set out in the engagement documentation. Delivery or transit-failure outcomes are handled via insurance and replacement coordination rather than refund, because once a US procurement chain is committed, the drug is committed.

Manufacturer context and global distribution

Kevzara is manufactured by Sanofi / Regeneron. Like most US specialty therapies, it is routed through a narrow set of authorized specialty wholesalers under DSCSA (Drug Supply Chain Security Act) track-and-trace rules. That is the same supply lane US specialty pharmacies use; cross-border named-patient access works by attaching destination-country regulatory documentation to a shipment that originates inside that authorized lane, not by sourcing outside it. Counterfeit and parallel-trade exposure is concentrated outside that lane, which is precisely why Reserve Meds will not source from secondary or grey-market channels regardless of price.

Serial-number traceability is preserved end-to-end. Every Kevzara pack or vial carries the US wholesaler's lot and serial-number documentation forward into the destination-country regulatory submission, which is what allows the destination regulator to verify provenance on inspection.

What your physician provides

For Reserve Meds to coordinate Kevzara, the treating physician provides a treating-rheumatologist prescription, a clinical justification letter documenting active RA or PMR and prior therapy / steroid history, baseline TB and viral hepatitis screening, lipid and LFT monitoring, and license verification. Reserve Meds does not substitute for treating-physician judgment, does not prescribe, and does not advise on individual patient suitability; that is the treating physician's role.

Common questions

Is Kevzara the same as tocilizumab?

Both are anti-IL-6R monoclonal antibodies. Tocilizumab is humanized; sarilumab is fully human. Specialist judgment on choice between them.

What is the steroid-sparing role in PMR?

IL-6R blockade allows many PMR patients to taper off corticosteroids that would otherwise be hard to stop, reducing cumulative steroid toxicity.

Does Kevzara require cold chain?

Yes. Refrigerated storage; can be at room temperature briefly before injection.

Is TB screening required?

Yes. Standard pre-biologic TB and viral hepatitis screening is part of the workup.

What labs are monitored on therapy?

Lipids, LFTs, neutrophil and platelet counts are part of label monitoring.

Indicative timing

Time-to-first-dose for Kevzara is dominated by destination-country regulatory turnaround on the named-patient or personal-import submission, not by US procurement (which is typically days, not weeks, for an authorized specialty wholesaler with serialized stock). In faster markets (UAE Ministry of Health and Prevention named-patient track, Saudi SFDA named-patient track), the regulatory clock is commonly under 4 weeks when the dossier is complete on first submission. In slower markets or where translations and additional attestations are required, the regulatory clock can extend to 6 to 10 weeks. Reserve Meds frames every Kevzara timeline as an indicative range with a defined gating event (regulator acknowledgement), not as a guaranteed delivery date.

Subsequent cycles are materially faster than the first cycle because the regulatory file, physician credentials, and import authorization are already on record. For chronic-use therapies like Kevzara, the first cycle carries the regulatory overhead; the rest is logistics.

Where Reserve Meds fits in

Reserve Meds is the named cross-border coordinator. A dedicated patient coordinator owns the case from intake through delivery, the clinical and regulatory teams handle the document chain, and a DSCSA-compliant specialty wholesaler is the source of every vial or pack. We work in service of the treating-physician relationship, not around it.

Patients deal with one named coordinator from intake through delivery. Physicians deal with a clinical-and-regulatory contact who speaks the language of the destination regulator and of US specialty pharmacy. That single-point-of-contact structure is deliberate: cross-border specialty access fails most often at the seams between parties, not inside any single step, and Reserve Meds is built to own the seams.

Next step

Submit a 60-second intake. Our clinical team will respond as our first cohort opens with case-specific feasibility, a country pathway, an indicative timeline, and a formal quote.

Start your case Or message us on WhatsApp